Ceyda ANAR, Gülistan KARADENİZ, Melike YÜKSEL YAVUZ, Gülru POLAT, Melih BÜYÜKŞİRİN, Mine GAYAF, Filiz GÜLDAVAL, Aysu AYRANCI, Fatma DEMİRCİ ÜÇSULAR, Merve AYIK TÜRK

3316

Malign Plevral Sıvılarda Plevral Sıvı ve Serum Nötrofil-Lenfosit Oranının Prognostik Etkisi

Amaç: Çeşitli araştırmalarda serum nötrofil-lenfosit oranının (sNLR) çeşitli kanser tiplerine sahip hastalarda uygun maliyetli ve yararlı bir prognostik faktör olarak kullanılabileceği bildirilmiştir. Malign plevral efüzyonda (MPE) NLR’nin prognoz üzerindeki klinik etkisini araştırdık. Yöntem: MPE tanısı alan tüm hastalar retrospektif olarak incelendi. sNLR ve malign plevra sıvısı NLR (mNLR) değeri, yaş, Eastern Cooperative Oncology Group (ECOG), histopatolojik tip, serum albümin ve laktat dehidrogenaz (LDH) ile sağkalım arasındaki ilişki araştırıldı. Bulgular: Çalışmaya toplam 222 hasta dahil edildi ve ortalama yaş 65,7 ± 11,5 idi. mNLR değeri ≥0,42 ve sNLR değeri ≥4,75 olan hastalarda sağkalımın daha kısa olduğu saptandı (p: 0,001). Çok değişkenli analizde mNLR değeri 0,42 ve / veya sNLR değeri ≥4,75 (Odds oranı (OR): 2,66, p: 0,001), serum LDH> 210 (OR = 1,8, p: 0,001) ve yaş> 65 (OR = 1.9, P = 0,001) olmasının sağkalımla ilişkili olduğu görüldü. Sonuç: sNLR ve mNLR, MPE’li hastalarda basit, kullanışlı ve uygun maliyetli bir prognostik faktör olarak kullanılabilir. Ayrıca, bu sonuçlar gelecekte mNLR ile ilgili daha fazla araştırmanın temel taşı olarak hizmet edebilir. Sonuçlarımızı genelleştirmek için daha fazla çalışmaya ihtiyaç duyulmasına rağmen, bu bilgiler MPE’li hastalar için en uygun tedaviyi belirlemede klinisyenlere ve hastalara fayda sağlayacaktır.

Prognostic Effects of Neutrophil-Lymphocyte Rates in Serum and Pleural Fluids in Malignant Pleural Fluids

Objective: Various studies have reported that the neutrophil-to-lymphocyte ratio in the serum (sNLR) may serve as a cost-effective and useful prognostic factor in patients with various cancer types. We investigated the clinical impact of NLR as a prognostic factor in malign pleural effusion (MPE) and sNLR on prognosis in MPE. Method: We retrospectively reviewed all of the patients who were diagnosed MPE. The relationship between sNLR and neutrophil-to-lymphocyte ratio in the malign pleural effusion (mNLR) value, age, Eastern Cooperative Oncology Group (ECOG), histopathologic type, serum albumin and lactate dehydrogenase (LDH) with survival were investigated. Results: A total of 222 patients with a mean age of 65.7±11.5 were included in the study. Patients with a mNLR value ≥0.42 and a serum NLR value ≥4.75 had a shorter survival (p: 0.000). Multivariate analysis, which showed that survival was significantly related mNLR value > 0.42 and/or sNLR value > 4.75 (Odds Ratio (OR): 2.66, %95 CI, 1,65-4,3 p: 0.001), serum LDH > 210 (OR = 1.8, %95 CI, 1,33-2,46 p: 0.001) and age > 65 (OR = 1.9, %95 CI, 1,41-2,55 p = 0.001). Conclusion: sNLR and mNLR may act as a simple, useful, and cost-effective prognostic factor in patients with MPE. Furthermore, these results may serve as the cornerstone of further research into the mNLR in the future. Although further studies are required to generalize our results, this information will benefit clinicians and patients in determining the most appropriate therapy for patients with MPE.
PDF

___

  • 1. Froudarakis ME. Pleural effusion in lung cancer: more questions than answers. Respiration. 2012;83(5):367- 76. https://doi.org/10.1159/000338169
  • 2. Roberts ME, Neville E, Berrisford RG, et al. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010;6 (Suppl2):ii32-40. https://doi.org/10.1136/thx.2010.136994
  • 3. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706-14. https://doi.org/10.1097/JTO.0b013e31812f3c1a
  • 4. Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. Management of a malignant pleural effusion: British thoracic society pleural disease guideline 2010. Thorax. 2010;65 Suppl 2:ii32-40. https://doi.org/10.1136/thx.2010.136994
  • 5. Light RW. Pleural diseases. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2013.
  • 6. Ekpe EE, Ikpe M, IN U. Palliative treatment of malignant pleural effusion. Diag Ther Stud. 2013;2(1):8-20.
  • 7. Hooper C, Lee YC, Maskell N. Investigation of a unilateral pleural effusion in adults: British thoracic society pleural disease guideline 2010. Thorax. 2010;65 Suppl 2:ii4- 17. https://doi.org/10.1136/thx.2010.136978
  • 8. Good JT Jr, Taryle DA, Sahn SA: The pathogenesis of low glucose, low pH malignant effusions. Am Rev Respir Dis 1985;131:737-41.
  • 9. Sahn SA, Good JT Jr: Pleural fluid pH in malignant effusions: diagnostic, prognostic, and therapeutic implications. Ann Intern Med. 1988;108:345-9. https://doi.org/10.7326/0003-4819-108-3-345
  • 10. Rodriguez-Panadero F, Lopez Mejias J: Low glucose and pH levels in malignant pleural effusions: diagnostic significance and prognostic value in respect to pleurodesis. Am Rev Respir Dis 1989;139:663-7. https://doi.org/10.1164/ajrccm/139.3.663
  • 11. Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-tolymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106:dju124. https://doi.org/10.1093/jnci/dju124
  • 12. Lee YS, Nam HS, Lim JH, Kim JS, Moon Y, Cho JH, Ryu JS, Kwak SM and Lee HL. Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients. BMC Cancer 2017;17:557. https://doi.org/10.1186/s12885-017-3550-8
  • 13. Paramanathan A, Saxena A, Morris DL. A systematic review and metaanalysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surg Oncol. 2014;23:31-9. https://doi.org/10.1016/j.suronc.2013.12.001
  • 14. Kang MH, Go SI, Song HN, Lee A, Kim SH, Kang JH, et al. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer. 2014;111:452-60. https://doi.org/10.1038/bjc.2014.317
  • 15. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammationbased neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88:218-30. https://doi.org/10.1016/j.critrevonc.2013.03.010
  • 16. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/ lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011;104:1288-95. https://doi.org/10.1038/bjc.2011.100
  • 17. Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res. 2010;16:5805-13. https://doi.org/10.1158/1078-0432.CCR-10-2245
  • 18. Clive AO, Kahan BC, Hooper CE, Bhatnagar R, Morley AJ, Zahan-Evans N, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014;69:1098-104. https://doi.org/10.1136/thoraxjnl-2014-205285
  • 19. Naito T, Satoh H, Ishikawa H, Yamashita YT, Kamma H, Takahashi H, et al. Pleural effusion as a significant prognostic factor in non-small cell lung cancer. Anticancer Res. 1997;17(6):4743-6.
  • 20. Zamboni MM, Teixeira da Silva Jr, Baretta R , Cunha ET and Cardoso GP. Important prognostic factors for survival in patients with malignant pleural effusion. BMC Pulmonary Medicine 2015;15:29 https://doi.org/10.1186/s12890-015-0025-z
  • 21. Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC, Uitterlinden AG, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam study. J Clin Oncol. 2006;24:5216-22. https://doi.org/10.1200/JCO.2006.07.1381
  • 22. McMillan DC. The systemic inflammation-based Glasgow prognostic score:decade of experience in patients with cancer. Cancer Treat Rev. 2013;39:534-40. https://doi.org/10.1016/j.ctrv.2012.08.003
  • 23. Shafique K, Proctor MJ, McMillan DC, Leung H, Smith K, Sloan B, et al. The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients. BMC Cancer. 2013;13:1. https://doi.org/10.1186/1471-2407-13-292
  • 24. Pine SR, Mechanic LE, Enewold L, Chaturvedi AK, Katki HA, Zheng YL, et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein,and risk of lung cancer. J Natl Cancer Inst. 2011;103:1112-22. https://doi.org/10.1093/jnci/djr216
  • 25. Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-smallcell lung cancer: an analysis of Japan multinational trial organisation LC00-03. Eur J Cancer. 2009;45:1950-8. https://doi.org/10.1016/j.ejca.2009.01.023
  • 26. Mallet S, Royston P, Waters R, Dutton S, Altman DG. Reporting performance of prognostic models in cancer: a review. BMC Med. 2010;8:21-31. https://doi.org/10.1186/1741-7015-8-21
  • 27. Royston P, Altman DG. External validation of a Cox prognostic model: principles and methods. BMC Med Res Methodol. 2013;13:33-9. https://doi.org/10.1186/1471-2288-13-33
  • 28. Anevlavis S, Kouliatsis G, Sotiriou I, Koukourakis MI, Archontogeorgis K, Karpathiou G, et al. Prognostic factors in patients presenting with pleural effusion revealing malignancy. Respiration. 2014;87(4):311-6. https://doi.org/10.1159/000356764
  • 29. Bielsa S, Salud A, Martínez M, Esquerda A, Martín A, Rodríguez-Panadero F, et al. Prognostic significance of pleural fluid data in patients with malignant effusion. Eur J Int Med. 2008;19:334-9. https://doi.org/10.1016/j.ejim.2007.09.014
İzmir Göğüs Hastanesi Dergisi-Cover
  • ISSN: 1300-4115
  • Başlangıç: 1986
  • Yayıncı: Ali Cangül
Arşiv
Sayıdaki Diğer Makaleler

Tübeküloz Tanısı ile Takip Edilen Hastalarda Primer Akciğer Kanseri Gelişme Oranı ve Hastaların Klinik Özellikleri

Berna KÖMÜRCÜOĞLU, Gülru POLAT, Merve Ayık TÜRK, Aysen Evkan ÖZTÜRK

COVID-19 Pandemisinin Etkisiyle Birlikte İstanbul’da Son Beş Yılın Hava Kirliliği Değerlendirilmesi

Sabri Serhan OLCAY, Nilüfer AYKAÇ, Pınar BOSTON, Berker ÖZTÜRK

Kısa Etkili Bronkodilatör Yanıtı Değerlendirmede %MMEF ile sGaw, Kısmi Reversibilite ile Reversibilite Arasında Belirleyici Tanısal Bir Parametre Olabilir mi?

Gökhan ERDOĞAN, Elif ALTUĞ, Sacide Rana IŞIK, Levent TABAK

Pandeminin Erken Döneminde Göğüs Hastalıkları Hastanesinin Covid Dışı Bir Servisinde COVID-19’un Klinik Özellikleri ve Bulaşma Yolları

Ceyda ANAR, Özgür BATUM, Gülistan KARADENİZ, Gülru POLAT, Dursun TATAR, Mine GAYAF, Filiz GÜLDAVAL, Aysu AYRANCI

İleri Evre Akciğer Kanserinde; Yaygın Kanser İnflamasyon İndeksi (ALI), Serum Nötrofil/Lenfosit Oranı (NLR), Trombosit/Lenfosit Oranının (PLR) Prognostik Değeri

Berna KÖMÜRCÜOĞLU, Aysen EVKAN ÖZTÜRK, Gamze KARAKURT, Özgür ÖZTÜRK

Malign Plevral Sıvılarda Plevral Sıvı ve Serum Nötrofil-Lenfosit Oranının Prognostik Etkisi

Ceyda ANAR, Gülistan KARADENİZ, Melike YÜKSEL YAVUZ, Gülru POLAT, Melih BÜYÜKŞİRİN, Mine GAYAF, Filiz GÜLDAVAL, Aysu AYRANCI, Fatma DEMİRCİ ÜÇSULAR, Merve AYIK TÜRK